Introducing Kardia 12L: The first of its kind 12-lead portable ECG | Learn More

AliveCor Logo

Our Products

AFib Screening
Data Integration Solutions
KardiaCare Plus
KardiaComplete
Kardia 12L

New

KardiaMobile 6L
AliveCor K1000
KardiaStation
KardiaPro
Kardia ECG Devices

Our Solutions

Health Systems
Clinical Trials
Payors
Employers
OEMs
Veterans Affairs

About

Leadership
Mission
Clinical Research
Our AI
For Consumers
The Human Component Film
Newsroom
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

12 Ways to Improve Adherence

PM360online.com

Specialty therapies face unique challenges surrounding patient safety, access to testing, mobility, and delays. Recent advancement of mobile ECGs help overcome these challenges, allowing patients to test within the privacy and convenience of their own home.

Leveraging AliveCor’s KardiaMobile 6L technology, IQVIA In Home Clinical Solutions pioneered a program among breast cancer patients that aimed to alleviate common pain points associated with ECG testing required for treatment.

The patients were provided a less invasive device which made it easier for them to take their own ECG readings. The program eliminated the need for the patients to travel to an office, significantly increasing the group’s adherence to treatment.

Key Takeaways

  • KardiaMobile 6L uniquely addresses challenges surrounding speciality therapies
  • The device offers a less invasive alternative to traditional 12-lead systems, mitigating additional and unnecessary pain points for cancer patients
  • Remote ECG monitoring can improve patient adherence to treatment

Read Full Article

In The News

12 Ways to Improve Adherence

PM360online.com | With treatment plans that require frequent ECG testing, patients with breast cancer are faced with even more challenges. Leveraging KardiaMobile® 6L, an IQVIA program alleviated the pains associated with traditional 12-lead systems.

At-Home Clinical Trials Are the Future

StatNews.com | Hybrid and decentralized clinical trials are rapidly advancing. To ensure DCT success, mobile digital health technologies, like portable ECGs, are proving more necessary than ever.

Remote Monitoring Boosts Decentralized Trials

PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.